monoclonal-antibody-manufacturing
8 Results
Advanced Search
Showing
Products (0)
Documents (0)
Site Content (8)
Narrow Your Results Use the filters below to refine your search
By Application
By Brand
By Industry
-
-
Event | A3P BioProduction International Congress | Merck
Next Generation Bioprocessing is considered to be any technology, expendable, or system which significantly changes the existing monoclonal antibody manufacturing template to deliver higher productivity, increased manufacturing flexibility, increased speed, and reduced risk. Meet our experts to get insights and perspectives on the on-going paradigm shift and evolution towards Next Generation Bioprocessing occurring in today's and tomorrow's biopharmaceutical landscape. -
Press Release: Merck to Acquire Natrix Separations to Advance Next-Generation Processing Capabilities
Merck today announced that it has entered into an agreement to acquire Natrix Separations, an Ontario, Canada-based provider of hydrogel membrane products for single-use chromatography. -
Managing Aggregates in Your Monoclonal Antibody (mAb) Process | Merck
Aggregates in mAb therapeutics pose a risk to patients. Are you considering how best to manage and remove aggregates across your template? -
Purification of mAbs and related proteins: Chromatographic methods, strategies and optimization | Biopharmaceutical Courses | Biopharmaceutical Manufacturing | Merck
This hands-on course provides a fundamental understanding of chromatographic methods and strategies to purify monoclonal antibodies and related molecules. -
Blood Typing Monoclonal Antibodies | IVD/OEM Materials and Reagents | Merck
For more than 25 years we are been the leader in the development of monoclonal antibodies for the blood grouping market. -
Finished Reagents | IVD/OEM Materials and Reagents | Merck
Merck's blood typing reagents are made from human or murine monoclonal antibodies and are formulated in low-protein diluents. -
Press Release: Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound
Merck will provide its Provantage® End-to-End development and manufacturing services to Y-mAbs Therapeutics, Inc. in support of Y-mAbs' monoclonal antibody in late stage clinical development